Latest & greatest articles for mometasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mometasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mometasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mometasone

1. Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. (PubMed)

Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is less than 2% (low eosinophil level). The appropriate treatment for these patients is unknown.In this 42-week, double-blind, crossover trial, we assigned 295 patients who were at least 12 years of age and who had mild, persistent asthma to receive mometasone (an inhaled glucocorticoid), tiotropium (a long-acting muscarinic (...) antagonist), or placebo. The patients were categorized according to the sputum eosinophil level (<2% or ≥2%). The primary outcome was the response to mometasone as compared with placebo and to tiotropium as compared with placebo among patients with a low sputum eosinophil level who had a prespecified differential response to one of the trial agents. The response was determined according to a hierarchical composite outcome that incorporated treatment failure, asthma control days, and the forced expiratory

2019 NEJM

2. Efficacy of mometasone furoate for nasal polyps: a protocol for systematic review of randomized controlled trials

Efficacy of mometasone furoate for nasal polyps: a protocol for systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

3. Mometasone

Mometasone Top results for mometasone - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for mometasone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

4. Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial (PubMed)

Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial Otitis media is one of the most common infections among children and is a complication in about 30% of common colds. The most common complication of acute otitis media is otitis media with effusion. Some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. However, current information is inadequate (...) in this issue.To compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending Koodakan hospital in Bandar Abbas, Iran.This randomized controlled trial was done on 2- to 6-year-old children attending Koodakan Hospital in Bandar Abbas, southern Iran, in 2014. Patients were divided into three groups of montelukast, mometasone, and control group. Audiometry was done for all patients at baseline and four weeks after treatment. Patients were

Full Text available with Trip Pro

2017 Electronic physician

5. Mometasone Furoate (Asmanex Twisthaler) for asthma. It is inhaled, but does not aspire...for something more

Mometasone Furoate (Asmanex Twisthaler) for asthma. It is inhaled, but does not aspire...for something more 2015. DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management Content tools Share it It is inhaled, but does not aspire (...) ...for something more Mometasone furoate is an inhaled glucocorticoid indicated in the maintenance treatment of persistent asthma. No advantage has been shown in terms of relevant clinical outcomes with respect to other inhaled corticosteroids. The profile of adverse effects and the administration regimen of mometasone are similar to that of other inhaled corticoids. Enviar comentario You can send us a comment or suggestion and we will respond to most frequently asked questions Competing interests (complete

2015 Drug and Therapeutics Bulletin of Navarre (Spain)

6. Asmanex HFA (mometasone furoate) Inhalation Aerosol

Asmanex HFA (mometasone furoate) Inhalation Aerosol Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Asmanex HFA (mometasone furoate) Inhalation Aerosol Company: Merck Sharp & Dohme Corp. Application No.: 205641 Approval Date: 4/25/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2014 FDA - Drug Approval Package

7. Mometasone / formoterol - Asthma maintenance

Mometasone / formoterol - Asthma maintenance Common Drug Review CDEC Meeting – November 21, 2012 Notice of CDEC Final Recommendation – December 19, 2012 Page 1 of 5 © 2012 CADTH CDEC FINAL RECOMMENDATION MOMETASONE FUROATE/FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL – REQUEST FOR ADVICE (Zenhale – Merck Canada Inc.) Indication: Asthma Maintenance (Adults, Children 12 Years or Older) Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mometasone furoate/formoterol (...) fumarate dihydrate (Zenhale) be listed with the following condition: List in a manner similar to other combination inhaled corticosteroid/long-acting beta agonists (ICS/LABAs). Reasons for the Recommendation: 1. Three randomized controlled trials (RCTs) demonstrated that combination use of mometasone/formoterol was more efficacious than mometasone monotherapy for improving lung function in patients with asthma, as measured by the forced expiratory volume in one second (FEV 1 ). 2. The individual

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

8. Mometasone furoate - Asthma, (Bronchial) Prophylactic management of steroid responsive

Mometasone furoate - Asthma, (Bronchial) Prophylactic management of steroid responsive Common Drug Review CDEC Meeting – April 18, 2012 Notice of CDEC Final Recommendation – May 16, 2012 Page 1 of 5 © 2012 CADTH CDEC FINAL RECOMMENDATION MOMETASONE FUROATE (Asmanex – Merck Canada Inc.) Indication: Asthma, (Bronchial) Prophylactic Management of Steroid-Responsive Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mometasone furoate be listed for the prophylactic management (...) of steroid-responsive bronchial asthma. Reasons for the Recommendation: 1. Based on a systematic review including six randomized controlled trials (RCTs), mometasone demonstrated similar or greater efficacy compared with other available inhaled corticosteroids, based on improvements in lung function tests and symptom scores, and reductions in rescue medication use. 2. The daily cost of mometasone is similar to other available inhaled corticosteroids. Background: Mometasone furoate has a Health Canada

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

9. Mometasone furoate & formoterol - asthma

Mometasone furoate & formoterol - asthma CEDAC M Notice of © 2011 C MOME I Recomm The Can furoate/fo Reasons 1. The C unce mom early prima 2. There mom Backgro Zenhale long-acti indication older with on asthm metered formotero The Hea oral inha of mome Meeting – July CEDAC Fina ADTH TASONE F ndication: mendation: adian Exper ormoterol fu s for the Re Committee c rtain. The on etasone/form termination ary outcome e are no RC etasone/form ound: is a fixed-do ng beta-ago n for the ma h reversible (...) not be adequ ler providing nations of m 00/5 mcg. ily (morning mcg (given as ars of age a Page E INHALAT or Older) ometasone /formoterol to the efficacy was limited in for the afety of ed in Canad furoate) and lth Canada ars of age a uately contro g pressurized mometasone and evening s two inhala and older. 1 of 5 ION o be of by its a. d a and olled d and g) by tions CEDAC M Notice of © 2011 C Summar The Com (CDR): a pharmac issues im Clinical The syste minimum studies 4 • S m tw 1 • S p co flu co flu • S

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

10. Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol

Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol Drug Approval Package: Dulera (mometasone furoate and formoterol fumarate) NDA #022518 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol 100/5 and 200/5 micrograms Company: Schering Corporation Application No.: 022518 Approval Date: 06/22/2010 Persons with disabilities having problems accessing the PDF files below

2010 FDA - Drug Approval Package

11. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials

Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

12. Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo

Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo Article Text

2007 Evidence-Based Medicine (Requires free registration)